health care

Eisai Co., Ltd.



Shareholder Return

Eisai's shareholder return is to be determined by a resolution of the Board of Directors as specified in the Company's Articles of Incorporation.

The Company is devoted to providing sustainable and stable dividends under a strong balance sheet in consideration of its consolidated financial performance along with dividend on equity (DOE)*1 and free cash flow. Acquisition of treasury stock will be carried out appropriately after factors such as the market environment and capital efficiency are taken into account.

DOE is an index contributing to shareholder value that encompasses both the dividend payout ratio, which measures the extent to which profits are distributed to shareholders in the form of dividends, and return on equity (ROE)*2, which measures capital efficiency. Also, DOE shows the ratio of dividend to shareholders' equity and thus serves as an index for balance sheet management.

The Company intends to set the interim dividend for the period (at the end of the second quarter) at ¥70 per share, and expects to set the year-end dividend at ¥80 per share (total dividend of ¥150 per share for the year).

*1 DOE (Dividend on equity attributable to owners of the parent ratio) = Total dividend payout / Equity attributable to owners of the parent

*2 ROE (Profit ratio to equity attributable to owners of the parent) = Profit attributable to owners of the parent / Equity attributable to owners of the parent

Dividends per Share/DOE



Stock Information

(Figures are rounded.)

Full year Six months ended September 30

Revenue (Billions of yen)



R&D Expenses (Billions of yen)



Operating Profit (Billions of yen)



Profit for the Period (Billions of yen)



Revenue from Major Products

Percentage figures indicate the percentage of total sales.



Revenue by Reporting Segment

Percentage figures indicate the percentage of total sales.



Ongoing Research & Development Projects

Development progress since April 2014 is as follows. (As of October 31, 2014)

Therapeutic Areas	Product Name (Research Code)	Form	Description	Region	Development Status			
					Phase II	Phase III	Submission	Approved
Oncology and Supportive Care	***Halaven*** **(E7389)**	Injection	Anticancer agent/Additional indication: Second-line treatment for breast cancer	Europe				Jun.
	Lenvatinib (E7080)	Oral	Anticancer agent/Thyroid cancer	Japan				
				U.S./ Europe				
	DC Bead **(E7040)**	Embolic agent	Embolic bead/Additional indication: Transcatheter arterial embolization (TAE) of hypervascular tumors	Japan				
Neurology	***Aricept*** **(E2020)**	Oral	Anti-Alzheimer's agent/Additional indication: Dementia with Lewy bodies	Japan				Sep.
	Fycompa **(E2007)**	Oral	Antiepileptic agent/Additional indication: Primary generalized Tonic-Clonic seizures	U.S./ Europe				
	Inovelon/ Banzel **(E2080)**	Oral	Antiepileptic agent/Additional indication: Pediatric Lennox-Gastaut syndrome (LGS)	U.S.				

Regarding the aldose reductase inhibitor AS-3201, a Phase II/III study conducted in Europe and the United States was completed, however upon considering the further development strategy based on results, the Company has discontinued development.

- Eisai Files Applications for Indication Approval of Anticancer Agent Lenvatinib (Generic Name) as a Treatment for Thyroid Cancer in Japan, Europe and the United States

Eisai filed applications to regulatory authorities in Japan in June 2014 and in the United States and Europe in August for indication approval of lenvatinib (generic name) as a treatment for thyroid cancer. Lenvatinib was granted Orphan Drug Designation for thyroid cancer in Japan, Europe and the United States. The treatment was also granted an accelerated review in Europe and a priority review in the United States. Eisai aims to obtain approval as quickly as possible in order to further contribute to increasing the benefits for patients with thyroid cancer and their families.

- Eisai Submits Applications for Antiepilepsy Agent *Fycompa*® in Europe and the United States Seeking an Indication Expansion

In August 2014, Eisai submitted applications to regulatory authorities in Europe and the United States for an indication expansion of *Fycompa*® as an adjunctive therapy for the treatment of primary generalized tonic-clonic seizures. *Fycompa* is a first-in-class antiepileptic agent discovered and developed by Eisai. Through its extensive product lineup, including *Fycompa*, Eisai seeks to make continued contributions to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

• Eisai Receives Approval in Japan on Treatment for Dementia with Lewy Bodies

In September 2014, Eisai's anti-Alzheimer's agent, *Aricept*®, received approval for a new indication for dementia with Lewy bodies (DLB) in Japan. This marks the first time a treatment has been approved for DLB anywhere in the world.

DLB was discovered by Dr. Kenji Kosaka, Professor Emeritus of Yokohama City University. DLB is considered to be one of Japan's three major types of dementia, alongside Alzheimer's disease and vascular dementia.

As the originator of *Aricept*, through this additional indication for the treatment of DLB, Eisai will ensure and provide information on diagnosis, treatment and care of DLB and contribute to improving the quality of life of patients.

• KAN Research Institute Commences Full-Scale Operation at New Facility